Redeye: Vitrolife Q1 update - Entering 2024 with low growth
Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024. The combined effect from insourcing (PGT-A), ERA and EmbryoMap switching will likely contribute to a considerable headwind in Q2 (ERA could improve). Our updated view is a base case valuation of SEK 220 (245), a Bull Case of SEK 365(400), and a Bear Case of SEK 95 (100).
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/